首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Is irradiation a justifiable treatment of choroidal melanoma? Analysis of published results.
【2h】

Is irradiation a justifiable treatment of choroidal melanoma? Analysis of published results.

机译:放射线治疗脉络膜黑色素瘤是否合理?分析已发布的结果。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Analysis of the literature shows that dissemination of choroidal melanomas generally occurs after the 7 mm diameter stage, that doubling times of uveal melanomas vary from 30 to 365 days, and that death from metastases occurs 30-40 doubling times after dissemination. Tumour related death within three years after therapy is caused by pre-existing metastases. Survival rates for less than four years after therapy are therefore irrelevant in evaluating the efficacy of therapeutic regimens. Considerably higher postirradiation than postenucleation death rates after a mean 10-year follow-up period have been reported, and this difference can be explained by a reported mean clinical tumour regression rate of 31% two years after irradiation and histopathological studies which revealed that 42 out of 43 irradiated melanomas contained viable tumour, while only 50% showed necrosis. The doubtful value of preserving vision does not justify the high risk of avoidable death from metastases in irradiated patients.
机译:文献分析表明,脉络膜黑色素瘤的扩散通常发生在直径为7 mm的阶段之后,葡萄膜黑色素瘤的倍增时间为30至365天不等,而转移引起的转移死亡则是扩散后30-40倍。治疗后三年内与肿瘤相关的死亡是由预先存在的转移引起的。因此,治疗后少于四年的存活率与评估治疗方案的疗效无关。据报道,平均10年的随访期后,放射后的死亡率比摘除核后的死亡率高得多,这种差异可以通过放射后两年的平均临床肿瘤消退率31%和组织病理学研究来解释,其中42%在43例受辐照的黑色素瘤中,有活瘤,而只有50%表现出坏死。保留视力的可疑价值并不能证明受辐照患者转移引起的可避免死亡的高风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号